tiprankstipranks

Anatara Lifesciences Reports Promising GaRP-IBS Trial Results

Story Highlights
Anatara Lifesciences Reports Promising GaRP-IBS Trial Results

Confident Investing Starts Here:

Anatara Lifesciences Ltd ( (AU:ANR) ) has shared an update.

Anatara Lifesciences Ltd has completed Stage 2 of its GaRP-IBS Phase II trial, revealing positive trends in symptomatic relief for pain and abdominal distension, although the primary endpoint of statistical significance in IBS-SSS reduction was not achieved. The trial’s secondary endpoint showed significant improvement in anxiety scores, and the company is considering potential commercial discussions based on these outcomes.

More about Anatara Lifesciences Ltd

Anatara Lifesciences Ltd is a developer of evidence-based, innovative products focusing on significant unmet needs in human health, particularly conditions involving the gastrointestinal tract (GIT).

Average Trading Volume: 2,597,358

Technical Sentiment Signal: Strong Sell

Current Market Cap: A$1.28M

Find detailed analytics on ANR stock on TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1